Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized Controlled Trial of Triple Therapy With Conventional Proton Pump Inhibitor vs Triple Therapy With Vonoprazan as First Line Therapy for Helicobacter Pylori Gastritis

Next Previous
Trial Profile

A Randomized Controlled Trial of Triple Therapy With Conventional Proton Pump Inhibitor vs Triple Therapy With Vonoprazan as First Line Therapy for Helicobacter Pylori Gastritis

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 06 Oct 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Vonoprazan (Primary) ; Amoxicillin; Clarithromycin; Esomeprazole; Omeprazole; Rabeprazole
  • Indications Gastritis; Helicobacter pylori infections
  • Focus Therapeutic Use
  • Acronyms TRIVON

Most Recent Events

  • 03 Jun 2022 Primary endpoint (Eradication rates of Helicobacter pylori determined by Carbon-13 urea breath test or biopsy) has been met, according to Results published in the Alimentary Pharmacology and Therapeutics.
  • 03 Jun 2022 Status changed from recruiting to completed, according to Results published in the Alimentary Pharmacology and Therapeutics.
  • 03 Jun 2022 Results assessing the non-inferiority of 1-week vonoprazan-based triple therapy versus 2-week PPI-based triple therapy as first-line H. pylori eradication in a multiracial Asian cohort, published in the Alimentary Pharmacology and Therapeutics.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top